Identification and Characterization of the Biomarker in Synovial Fluid for Hyaluronic Acid Therapy in Osteoarthritis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Osteoarthritis
- Sponsor
- National Taiwan University Hospital
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- To study the protein expression of synovial fluid for hyaluronic acid therapy in osteoarthritis
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to use the proteomic analysis of synovial fluid to perform the comprehensive investigation of the biomarker that will be useful to assign the tratment effectiveness of five weekly intra-articular HA injection.
Detailed Description
The intra-articular injection with HA is an accepted therapy for OA. However, the exact regulation of HA treatment is unclear. Compared the expression SF proteome from OA patients who received HA/800 treatment or not (post and pre-HA treatment) may be possible to identify the protein that response to the HA treatment and apply this to prognosis of OA. We used two-dimensional difference gel electrophoresis (2D-DIGE) combined with matrix-assisted laser desorption ionization time of light mass spectrometry (MALDI-TOF) to determine the differentially displayed proteins in human SF. Finally, we used Western blotting and ELISA analysis to validate the potential biomarkers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of osteoarthritis
- •Accept the intra-articular HA injection therapy
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
To study the protein expression of synovial fluid for hyaluronic acid therapy in osteoarthritis
Time Frame: up to 12 months
We used two-dimensional difference gel electrophoresis (2D-DIGE) combined with matrix-assisted laser desorption ionization time of light mass spectrometry (MALDI-TOF) to determine the differentially displayed proteins in human synovial fluid.